Mesenchymal precursor cell

To provide an update on the ongoing multi-centre Phase 2 clinical trial of the proprietary mesenchymal precursor cell (MPC) technology in patients with heart attacks, a press conference was held by the doctors at Houston’s Texas Heart Institute last Saturday.

Allogeneic, stem cell therapy

This is the first trial in the world to evaluate an allogeneic, stem cell therapy injected directly into damaged heart muscle by cardiac catheter.The trial’s 25 patients are currently being enrolled at multiple sites in the United States by Mesoblast’s (ASX:MSB; USOTC:MBLTY) sister company, Angioblast Systems Inc. Patients will get either placebo or one of three gradually increasing doses of the proprietary adult stem cells.

Cardiac catheter

It has been counted the first trial in the world to examine an allogeneic stem cell therapy injected directly into damaged heart muscle by cardiac catheter. 25 patients are currently being enrolled at multiple sites in the United States by Mesoblast’s (ASX: MSB; USOTC: MBLTY) sister company, Angioblast Systems Inc for the trial.

(more…)